



261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Batchworth LLC
License Number: CLTV-0372

Sample ID: 20260428-31376
Sample Name: Dantes Inferno
Sample Lot: HL-17
Sample Matrix: Flower
Date Received: 4/29/2026
Date Reported: 5/7/2026
Date Tested: 5/1/2026



| Total Cannabinoids | | |
|----------------------------|---------------|----------------|
| | % | mg/g |
| Total THC: | 17.473 | 174.730 |
| Total CBD: | -- | -- |
| Total Cannabinoids: | 22.148 | 221.483 |

Total theoretical CBD % = (CBD%) + (CBDA% * 0.877)
Total theoretical THC % = (delta-9-THC%) + (THCA% * 0.877)

Potency

Standard potency analysis utilizing High Performance Liquid Chromatography (HPLC; SOP-102-OA) | Test ID: #103548

| Analyte | % (Dry) | mg/g (Dry) | % | mg/g | LOD (mg/g) | LOQ (mg/g) |
|---------|---------|------------|--------|---------|------------|------------|
| CBC | ND | ND | ND | ND | 0.0003 | 0.0040 |
| CBCA | 0.536 | 5.357 | 0.488 | 4.877 | 0.0002 | 0.0040 |
| CBD | ND | ND | ND | ND | 0.0008 | 0.0040 |
| CBDA | ND | ND | ND | ND | 0.0002 | 0.0040 |
| CBDV | ND | ND | ND | ND | 0.0008 | 0.0040 |
| CBDVA | ND | ND | ND | ND | 0.0001 | 0.0040 |
| CBG | < LOQ | < LOQ | < LOQ | < LOQ | 0.0009 | 0.0040 |
| CBGA | 0.592 | 5.921 | 0.539 | 5.391 | 0.0001 | 0.0040 |
| CBN | ND | ND | ND | ND | 0.0004 | 0.0040 |
| CBNA | ND | ND | ND | ND | 0.0002 | 0.0040 |
| D8 THC | ND | ND | ND | ND | 0.0012 | 0.0040 |
| D9 THC | < LOQ | < LOQ | < LOQ | < LOQ | 0.0016 | 0.0049 |
| D10 THC | ND | ND | ND | ND | 0.0004 | 0.0040 |
| THCA | 19.924 | 199.236 | 18.140 | 181.404 | 0.0002 | 0.0040 |
| THCV | ND | ND | ND | ND | 0.0016 | 0.0049 |
| THCVA | 1.097 | 10.969 | 0.999 | 9.987 | 0.0002 | 0.0040 |

Moisture & Water Activity PASS

Water Activity and Moisture Content Analysis (SOP-120-OA) | Test ID: #103636

| Analyte | Result (%) | Limit | Pass/Fail |
|----------------|------------|-------|-----------|
| Moisture | 8.95 | 13.00 | PASS |
| Water Activity | 0.33 | 0.65 | |

Callie Chapman

Callie Chapman
 Lab Director
 5/7/2026

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.





261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Batchworth LLC
License Number: CLTV-0372

Sample ID: 20260428-31376
Sample Name: Dantes Inferno
Sample Lot: HL-17
Sample Matrix: Flower
Date Received: 4/29/2026
Date Reported: 5/7/2026
Date Tested: 5/1/2026



Total Terpenes (%) : 0.6498

| Dominant Terpenes (%) | |
|-----------------------|--------|
| beta-caryophyllene | 0.2154 |
| Limonene | 0.0761 |
| Myrcene | 0.074 |
| alpha-Humulene | 0.0733 |
| Ocimene | 0.0661 |

Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #103549

| Analyte | Result (%) | Result (mg/g) | LOD (mg/g) | LOQ (mg/g) |
|-----------------------|---------------|---------------|------------|------------|
| 3-Carene | ND | ND | 0.000002 | 0.001 |
| alpha-Bisabolol | 0.0598 | 0.598 | 0.000003 | 0.001 |
| alpha-Humulene | 0.0733 | 0.733 | 0.000002 | 0.001 |
| alpha-Pinene | 0.0092 | 0.092 | 0.000001 | 0.001 |
| alpha-Terpinene | ND | ND | 0.000001 | 0.001 |
| alpha-Terpinolene | 0.0066 | 0.066 | 0.000004 | 0.001 |
| beta-caryophyllene | 0.2154 | 2.154 | 0.000004 | 0.001 |
| beta-Pinene | 0.0217 | 0.217 | 0.000002 | 0.001 |
| Camphene | 0.0033 | 0.033 | 0.000001 | 0.001 |
| Caryophyllene Oxide | 0.0149 | 0.149 | 0.000011 | 0.001 |
| Eucalyptol | ND | ND | 0.000002 | 0.001 |
| gamma-Terpinene | ND | ND | 0.000002 | 0.001 |
| Geraniol | ND | ND | 0.000008 | 0.003 |
| Guaiol | ND | ND | 0.000007 | 0.001 |
| Isopulegol | ND | ND | 0.000005 | 0.001 |
| Isopropyl Toluene | ND | ND | 0.000003 | 0.001 |
| Limonene | 0.0761 | 0.761 | 0.000002 | 0.001 |
| Linalool | 0.0097 | 0.097 | 0.000003 | 0.001 |
| Nerolidol | 0.0197 | 0.197 | 0.000007 | 0.001 |
| Myrcene | 0.074 | 0.74 | 0.000003 | 0.001 |
| Ocimene | 0.0661 | 0.661 | 0.000002 | 0.001 |
| Total Terpenes | 0.6498 | 6.498 | | |



Callie Chapman

Callie Chapman
 Lab Director
 5/7/2026

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.





261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Batchworth LLC
License Number: CLTV-0372

Sample ID: 20260429-31402
Sample Name: Dantes Inferno
Sample Lot: HL-17
Sample Matrix: Flower
Date Received: 4/29/2026
Date Reported: 5/7/2026
Date Tested: 4/30/2026



Pathogens PASS

Microbiological screening utilizing qPCR (SOP-130-OA) | Test ID: #103641

| Analyte | Result | Pass/Fail |
|--------------|---------------|-----------|
| A. Fumigatus | None Detected | PASS |
| A. Niger | None Detected | PASS |
| A. Flavus | None Detected | PASS |
| A. Terreus | None Detected | PASS |
| STEC | None Detected | PASS |
| Salmonella | None Detected | PASS |



Callie Chapman

Callie Chapman
 Lab Director
 5/7/2026

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.





261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Batchworth LLC
License Number: CLTV-0372

Sample ID: 20260428-31379
Sample Name: GG, DI, MC, GB
Sample Lot: HL-17
Sample Matrix: Flower
Date Received: 4/29/2026
Date Reported: 5/7/2026
Date Tested: 4/30/2026



Pesticides Pass

Residual pesticide analysis utilizing Liquid Chromatography – Mass Spectrometry (LC-MSMS; SOP-070-OA) - **Limit units: ppm** | Test ID: #103557

| Analyte | Pass/Fail | Result (ppm) | Limit | LOD (ppm) | LOQ (ppm) |
|---------------|-----------|--------------|---------|----------------------|----------------------|
| Abamectin B1a | Pass | ND | 0.10000 | 0.00687 | 0.02081 |
| Abamectin B1b | Pass | ND | 0.10000 | 0.00133 | 0.00405 |
| Acephate | Pass | ND | 0.10000 | 0.02214 | 0.06710 |
| Acequinocyl | Pass | ND | 0.10000 | 0.02276 | 0.06897 |
| Azoxystrobin | Pass | ND | 0.10000 | 0.01262 | 0.03825 |
| Bifenazate | Pass | ND | 0.10000 | 0.01232 | 0.03734 |
| Bifenthrin | Pass | ND | 3.00000 | 0.04612 | 0.13976 |
| Carbaryl | Pass | ND | 0.50000 | 0.01039 | 0.03149 |
| Chlorpyrifos | Pass | ND | 0.04000 | 0.00702 | 0.02128 |
| Cypermethrin | Pass | ND | 1.00000 | 0.02839 | 0.08604 |
| Etoxazole | Pass | ND | 0.10000 | 0.00915 | 0.02772 |
| Imazalil | Pass | ND | 0.04000 | 0.00664 | 0.02012 |
| Imidacloprid | Pass | ND | 5.00000 | 0.02001 | 0.06063 |
| Myclobutanil | Pass | ND | 0.10000 | 0.01691 | 0.05123 |
| Spinosyn A | Pass | ND | 0.10000 | 0.00632 | 0.01916 |
| Spinosyn D | Pass | ND | 0.10000 | 0.00256 | 0.00775 |
| Pyrethrins | Pass | ND | 0.50000 | 0.00022 0.00498 * | 0.00072 0.00015 * |

* Pyrethrins action limit represents sum of isomers I & II



Callie Chapman

Callie Chapman
 Lab Director
 5/7/2026

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

